Completed PHASE2 INTERVENTIONAL 2-arm NCT04987242

An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)

An Inpatient, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects

Sponsor: Allena Pharmaceuticals

Conditions Chronic Kidney Diseases Gout Hyperuricemia

Updated 4 times since 2021 Last updated: Jun 20, 2023 Started: Jul 16, 2021 Primary completion: Mar 2, 2022 Completion: Mar 2, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Kidney Diseases and Gout and is currently completed. Allena Pharmaceuticals leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jul 2023 — Jul 2024 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Sep 2021 — Jul 2023 [monthly]

Recruiting PHASE2

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allena Pharmaceuticals

Data source: Allena Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tempe, United States